By Suherman Candra Maholtra 
A groundbreaking investigation conducted by researchers at the University of Virginia School of Medicine has revealed a significant and previously unrecognized long-term consequence of severe respiratory illnesses. The study, spearheaded by experts at UVA Health’s Beirne B. Carter Center for Immunology Research and the UVA Comprehensive Cancer Center, suggests that severe cases of COVID-19 and influenza may trigger lasting changes in the lungs that facilitate the development and rapid progression of lung cancer. Published in the prestigious scientific journal Cell, the findings indicate that the biological "aftershocks" of a severe viral infection can persist for months or even years, creating a fertile environment for oncogenesis.
While the immediate dangers of viral pneumonia and acute respiratory distress syndrome (ARDS) are well-documented, the medical community has long sought to understand the potential for these infections to leave a lasting pathological footprint. The UVA research team, led by Jie Sun, PhD, discovered that severe infections fundamentally alter the immune landscape of the lungs. However, the study also offers a beacon of hope: the data suggests that timely vaccination significantly mitigates these risks by preventing the initial severity of the infection, thereby shielding the lungs from the inflammatory damage that leads to cancer.
The Biological Mechanism: How Infections Prime the Lungs for Malignancy
To understand the link between viral infection and cancer, the researchers utilized a dual-track approach, combining controlled laboratory experiments on mice with an extensive analysis of human clinical data. The core of their discovery lies in the behavior of specific immune cells—neutrophils and macrophages—which serve as the body’s first line of defense against respiratory pathogens.
Under normal circumstances, these cells identify and eliminate viruses, eventually returning the lung tissue to a state of homeostasis. However, in cases of severe infection, these cells can become "reprogrammed" into a pro-tumor state. The UVA team observed that after a severe bout of COVID-19 or influenza, certain neutrophils began behaving abnormally, contributing to a persistent, low-grade inflammatory environment. This "chronic inflammation" acts as a catalyst for cancer, providing the signals necessary for mutated cells to survive, multiply, and eventually form tumors.
Furthermore, the study identified significant alterations in the epithelial cells that line the lungs and the alveoli, the tiny air sacs where oxygen exchange occurs. These structural changes, combined with a dysregulated immune response, create what the scientists describe as "immune scarring." This environment not only makes it easier for new cancers to take hold but also appears to accelerate the growth of existing, undetected malignancies.
Statistical Correlation: Analyzing the Human Impact
The clinical implications of the study are supported by a rigorous analysis of patient outcomes. By examining medical records of individuals who had been hospitalized with COVID-19, the researchers identified a 1.24-fold increase in the incidence of lung cancer compared to those who did not experience severe respiratory distress. This increased risk remained statistically significant even after the researchers accounted for known risk factors, such as smoking history, age, and pre-existing comorbidities.
Interestingly, the risk was strictly tied to the severity of the initial illness. Patients who experienced only mild cases of COVID-19 or influenza did not show an increased risk of lung cancer. In some instances, those with mild infections actually showed a slight decrease in cancer incidence, suggesting that a robust but controlled immune response might actually have a protective effect, whereas an overactive, damaging response does the opposite.
"A bad case of COVID or flu can leave the lungs in a long-lasting ‘inflamed’ state that makes it easier for cancer to take hold later," explained Dr. Sun, who serves as the co-director of UVA’s Carter Center. "The encouraging news is that vaccination largely prevents those harmful changes for cancer growth in the lung."
The Protective Role of Vaccination
The study highlights vaccination as a primary tool for cancer prevention in the context of respiratory health. By preventing the progression from a mild infection to a severe, hospitalized case, vaccines effectively block the cascade of inflammatory events that lead to pro-tumor immune changes.
The data suggests that the immune system of a vaccinated individual is "trained" to handle the virus efficiently, minimizing the collateral damage to lung tissue. This finding adds a new layer to the public health argument for annual flu shots and COVID-19 boosters. Beyond preventing acute hospitalization and death, these vaccines may serve as an indirect form of oncology care, reducing the long-term "fallout" that can lead to a cancer diagnosis years down the line.
Clinical Recommendations: A New Paradigm for Lung Cancer Screening
The findings have led the UVA research team to advocate for a shift in how doctors monitor patients who have survived severe respiratory crises. Currently, lung cancer screening is primarily focused on individuals with a significant smoking history. However, the study suggests that a history of severe viral pneumonia should perhaps be treated as a similar high-risk indicator.
Jeffrey Sturek, MD, PhD, a UVA physician-scientist and collaborator on the study, emphasized the need for heightened vigilance. "We’ve known for a long time that things like smoking increase the risk for lung cancer," Sturek said. "The results from this study suggest that we may need to think about severe respiratory viral infection similarly. For example, in some patients who are at high risk for lung cancer based on smoking history, we recommend close monitoring with routine screening CT scans of the lungs to catch cancer early. In future studies, we may want to consider a similar approach after severe respiratory viral infection."
By integrating a patient’s history of severe infection into their oncological risk profile, physicians may be able to detect lung cancer in its earliest, most treatable stages. This is particularly crucial given that lung cancer often remains asymptomatic until it has reached an advanced state, where the five-year survival rate drops significantly.
Chronology and Context: The Evolution of the Research
The genesis of this study dates back to the early waves of the COVID-19 pandemic, when clinicians at UVA and globally began noticing unusual patterns of pulmonary sequelae in "long-haul" patients. While initial research focused on pulmonary fibrosis and reduced lung capacity, Dr. Sun and his colleagues began to look deeper into the cellular shifts occurring within the lung microenvironment.
Over a period of several years, the team monitored mouse models post-infection, observing the gradual development of tumors. Simultaneously, they utilized large-scale health databases to track the long-term outcomes of human patients. The convergence of these two data streams led to the definitive findings published this month.
The research was a multi-disciplinary effort, involving specialists in immunology, oncology, infectious disease, and bioinformatics. The study was funded by several grants from the National Institutes of Health (NIH), as well as support from the American Lung Association and various UVA fellowships. The publication of their findings in Cell marks a significant milestone in post-pandemic medical research, providing a roadmap for future investigations into the "viral-cancer link."
Broader Implications and Public Health Impact
With tens of millions of people worldwide having experienced severe COVID-19, the potential public health burden is substantial. The researchers warn that the "long-term pulmonary sequelae" of the pandemic could manifest as a surge in lung cancer cases over the next decade.
"Our goal is to help doctors identify who may be at higher risk of lung cancer after a severe infection, and develop targeted ways to prevent and treat lung cancer after prior pneumonia," Dr. Sun stated.
This study also places renewed focus on the Paul and Diane Manning Institute of Biotechnology at UVA, which is dedicated to accelerating the transition of laboratory discoveries into clinical treatments. By understanding the specific immune pathways that lead to cancer, researchers hope to develop new "immunotherapies" that can reverse the "pro-tumor" state of neutrophils and macrophages in survivors of severe pneumonia.
Institutional Excellence and the Path Forward
The research underscores the importance of UVA Health’s specialized centers. The Beirne B. Carter Center for Immunology Research continues to lead the way in studying the intersection of infection and chronic disease, while the UVA Comprehensive Cancer Center remains one of only 57 centers in the nation to hold the "comprehensive" designation from the National Cancer Institute.
As the medical community moves forward, the focus is expected to shift toward refining screening protocols and exploring therapeutic interventions that can "reset" the lung’s immune environment after a severe illness. For the general public, the message remains clear: maintaining up-to-date vaccinations is not just about avoiding a week of illness; it is a critical step in protecting long-term respiratory health and potentially preventing a future cancer diagnosis.
The team’s findings serve as a stark reminder that the body’s response to an acute crisis can have echoes that last a lifetime. By bridging the gap between infectious disease research and oncology, UVA scientists have opened a new chapter in the fight against lung cancer—one that prioritizes early prevention and a deeper understanding of the body’s complex immune memory.
